BRE 402
Description:
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Study Status: Approved
Phase Of Study:
BRE 402
Available in 4 location(s)
Description:
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Locations:
Hematology Oncology Clinic
8585 Picardy Avenue Suite 110
Baton Rouge, LA 70809
USA
Get Directions
844-482-4812
Messino Cancer Centers
551 Brevard Road
Asheville, NC 28806
USA
Get Directions
844-482-4812
Zangmeister Cancer Center
844-482-4812
Zangmeister Cancer Center
844-482-4812